Pharvaris (NASDAQ:PHVS) PT Lowered to $34.00 at Morgan Stanley

Pharvaris (NASDAQ:PHVS) had its price objective trimmed by Morgan Stanley from $35.00 to $34.00 in a research note issued to investors on Monday morning, Benzinga reports. The firm currently has an overweight rating on the stock.

Other equities analysts also recently issued reports about the stock. JMP Securities increased their price objective on shares of Pharvaris from $49.00 to $50.00 and gave the company a market outperform rating in a research note on Thursday, April 11th. Wedbush reiterated an outperform rating and set a $35.00 price objective on shares of Pharvaris in a research note on Thursday, April 11th.

Pharvaris Stock Performance

NASDAQ PHVS opened at $21.20 on Monday. The firm’s 50 day moving average price is $24.41 and its 200-day moving average price is $23.29. Pharvaris has a 52-week low of $7.93 and a 52-week high of $33.00. The company has a market cap of $675.01 million, a PE ratio of -7.46 and a beta of -3.12.

Institutional Investors Weigh In On Pharvaris

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. lifted its position in Pharvaris by 2.0% during the second quarter. Goldman Sachs Group Inc. now owns 56,951 shares of the company’s stock valued at $1,259,000 after acquiring an additional 1,115 shares during the last quarter. Qube Research & Technologies Ltd purchased a new stake in Pharvaris during the third quarter valued at approximately $54,000. UBS Group AG purchased a new stake in Pharvaris during the fourth quarter valued at approximately $32,000. Tower Research Capital LLC TRC purchased a new stake in Pharvaris during the third quarter valued at approximately $26,000. Finally, Bank of America Corp DE raised its holdings in shares of Pharvaris by 1,054.4% in the first quarter. Bank of America Corp DE now owns 5,772 shares of the company’s stock worth $105,000 after buying an additional 5,272 shares during the last quarter.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).